Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
GeneDx Holdings ( (WGS) ) just unveiled an update.
GeneDx Holdings Corp. announced its preliminary, unaudited financial results for the fourth quarter and full year of 2024, indicating expectations to exceed its revenue guidance with at least $299 million for the year and $92 million for the fourth quarter. The company also anticipates a full year adjusted gross margin of at least 64% and 68% in the fourth quarter, highlighting strong execution and profitability milestones, including positive operational cash flow and adjusted net income, positioning itself as a standard-bearer in the use of genetics in healthcare.
More about GeneDx Holdings
GeneDx Holdings Corp. is a leader in the healthcare industry, providing genomic insights to deliver improved health outcomes. The company offers industry-leading exome and genome tests that utilize extensive rare disease data sets to translate complex genomic information into clinical solutions, facilitating personalized health plans, drug discovery acceleration, and health system efficiencies.
YTD Price Performance: 12.24%
Average Trading Volume: 634,095
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $2.46B
Learn more about WGS stock on TipRanks’ Stock Analysis page.
